Comparative assessment of the magnitude of Hyperlipidemia in HIV-Infected patients receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral drugs

Abstract

Objective: To assess prevalence of hyperlipidemia in patients receiving lopinavir boosted with ritonavir (LPV/r) and atazanavir boosted with ritonavir (ATV/r) antiretroviral drugs. Methods: HIV-infected patients (300) were recruited in the study between December 2015 and April 2016. Lipid profile including triglycerides (TG), high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (LDL-C) were assessed. Results: Prevalence of derangement in TG was 71.0% in patients using LPV/r compared to 44% in those using ATV/r (P ¼ .01). Use of LPV/r was independently associated with increased total cholesterol (TC; P ¼ .001) and TG (P ¼ .0003). Females had raised levels of TC compared to males (P ¼ .00008). Body mass index of 25 kg/m2 was also associated with raised TC (P ¼ .002) and LDL-C (P ¼ .006). Conclusion: LPV/r was significantly associated with lipid derangements, indicating the need to regularly monitor lipid profile in patients using LPV/r.